tirzepatide side effects semaglutide side effects comparison vs semaglutide vs tirzepatide comparison efficacy

The SUMMIT trial found that tirzepatide, a long-acting agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, reduced the risk of the co-primary outcome a composite of death from cardiovascular causes or a worsening heart failure event by 38% versus placebo

See product packaging for additional safety information

A food-first approach should always be prioritised, focusing on nutrient-dense foods to maximise nutritional value within a reduced calorie intake

In-Office GLP-1 Injections for Your Convenience Semaglutide: $55 per injection Tirzepatide: $85 per injection